Dr. Derek M. Isrow

Dr. Isrow joined the University of Miami Department of Radiation Oncology faculty in 2018 where he is clinically focused on treating both pediatric and lymphoma patients as well as gastrointestinal and breast cancer patients. He is trained in state-of-the-art radiation therapy techniques including proton therapy, MRI-guided radiation therapy, stereotactic radiosurgery, and intensity modulated radiation therapy amongst several others. His research interests are mostly basic science related and involve improving tumor response to radiation therapy using various nanotechnologies and metabolic drugs. He also has built and maintains the pediatric research database which is currently looking into educational outcomes for children who underwent long courses of chemotherapy and radiation. He is heavily involved with the University of Miami Miller School of Medicine where he serves as a Lead Clinical Educator and teaches medical students various aspects of medicine, ethics, and professionalism. He attended college at Emory University in Atlanta where he received his Bachelor's of Science in Chemistry. He matriculated to the University of Miami in 2004 where he began his PhD in organometallic chemistry. He then went on to enroll in the University of Miami Miller School of Medicine in 2008 and graduated in 2013 with his MD PhD focusing on oncologic diseases. He then completed a transitional internship at St Joseph Hospital in Chicago in 2014 which included medical, surgical, and intensive care training. This was followed by residency in Radiation Oncology at the historic Henry Ford Hospital in 2018 where he served as chief resident. He received several honors and awards during this time for his novel research in radiosensitization and clinical outcomes. Dr. Isrow is a South Florida native who enjoys cooking, woodworking, and all outdoor activities with his wife, two young daughters, and a pair of very overweight golden retrievers.

Dr. Isrow is highly rated in 1 condition, according to our data. His clinical expertise encompasses Marginal Zone Lymphoma (MZL), Primary Lymphoma of the Brain, Squamous Cell Carcinoma of the Anal Canal (SCAC), and Anal Cancer.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles. Dr. Isrow is currently accepting new patients.